| [1] |
Sharma T, Krishnan AM, Lahoud R, et al. National trends in TAVR and SAVR for patients with severe isolated aortic stenosis[J]. J Am Coll Cardiol, 2022, 80(21):2054-2056.
|
| [2] |
Forrest JK, Deeb GM, Yakubov SJ, et al. 2-Year outcomes after transcatheter versus surgical aortic valve replacement in low-risk patients[J]. J Am Coll Cardiol, 2022, 79(9):882-896.
|
| [3] |
Altibi A, Ghanem F, Alhuneafat L, et al. TCT-324 Cerebral embolic protection devices and outcomes of transcatheter aortic valve replacement: insight from national readmission database 2017-2019[J]. J Am Coll Cardiol, 2022, 80(12_Supplement): B130.
|
| [4] |
Sato Y, Torii S, Kawai K, et al. TCT-325 Pathology of hypo-attenuated leaflet thickening (HALT) in CoreValve/Evolut self-expanding transcatheter aortic valve Bioprostheses[J]. J Am Coll Cardiol, 2022, 80(12_Supplement): B130-B130.
|
| [5] |
Deharo P, Leroux L, Theron A, et al. Long-term prognosis value of paravalvular leak and patient-prosthesis mismatch following transcatheter aortic valve implantation: insight from the France-TAVI Registry[J]. J Clin Med, 2022, 11(20):6117-6136.
|
| [6] |
Tirado-Conte G, Rodes-Cabau J, Pan M, et al. TCT-458 Transcatheter aortic valve replacement in patients with extra-small aortic annulus[J]. J Am Coll Cardiol, 2022, 80(12_Supplement): B184-B185.
|
| [7] |
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2021, 143(5):e35-e71.
|
| [8] |
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J, 2022, 43(7):561-632.
|
| [9] |
Jason Rogers, Bardeleben R, Michael G, et al. "Contemporary clinical and echocardiographic outcomes of 1000+ patients treated with mitraClip ™ G4: results from the EXPAND G4 Post Approval Study" TCT 2022.
|
| [10] |
Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients[J]. JACC Cardiovasc Interv, 2022, 15(24):2523-2536.
|
| [11] |
Goel K. "COAPT PAS: 1 year outcomes from 5 000 patients" ESC 2022[EB/OL]. [2023-06-01].
URL
|
| [12] |
TTang G. "One-year outcomes in patients with secondary MR outside the COAPT criteria: from the MitraClip ™ global EXPAND study" TVT 2022[EB/OL]. [2023-06-01].
URL
|
| [13] |
Rubbio A, Testa L, Grasso C, et al. Transcatheter edge-to-edge mitral valve repair in atrial functional mitral regurgitation:insights from the multi-center MITRA-TUNE registry[J]. Int J Cardiol, 2022,2(349):39-45.
|
| [14] |
Munafò AR. "Transcatheter mitral valve repair as bridge therapy to heart transplantation (MitraBridge)"EuroPCR 2022[EB/OL]. [2023-06-01].
URL
|
| [15] |
Alkhouli M. "Transcatheter edge-to-edge repair in patients with severe mitral regurgitation and cardiogenic shock: insights from the TVT registry"TCT 2022[EB/OL]. [2023-06-01].
URL
|
| [16] |
Raposeiras-Roubin S, Adamo M, Freixa X, et al. A score to assess mortality after percutaneous mitral valve repair[J]. J Am Coll Cardiol, 2022, 79(6):562-573.
|
| [17] |
Zahr F. "Transfemoral TMVR: intermediate-term outcomes from the intrepid early feasibility study". TCT 2022[EB/OL]. [2023-06-01].
URL
|
| [18] |
Eleid MF, Wang DD, Pursnani A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with annular calcification, rings, and bioprostheses[J]. J Am Coll Cardiol, 2022, 80(23):2171-2183.
|
| [19] |
Pan WZ. 1-year results of a multicenter trial of TEER with ValveClamp system in high-risk patients with DM. TCT 2022[EB/OL]. [2023-06-01].
URL
|
| [20] |
Hu K, Liu D, Störk S, et al. Echocardiographic determinants of one-year all-cause mortality in patients with chronic heart failure complicated by significant functional tricuspid regurgitation[J]. J Card Fail, 2017, 23(6):434-443.
|
| [21] |
Kundi H, Popma JJ, Cohen DJ, et al. Prevalence and outcomes of isolated tricuspid valve surgery among medicare beneficiaries[J]. Am J Cardiol, 2019, 123(1):132-138.
|
| [22] |
Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival[J]. J Am Coll Cardiol, 2004, 43(3):405-409.
|
| [23] |
Kodali S, Hahn RT, George I, et al. Transfemoral tricuspid valve replacement in patients with tricuspid regurgitation: TRISCEND study 30-day results[J]. JACC Cardiovasc Interv, 2022, 15(5):471-480.
|
| [24] |
Teiger E, Nejjari M, Lim P, et al. First-in-human implantation of the Topaz transcatheter tricuspid valve replacement system[J]. EuroIntervention, 2022, 18(10):862-864.
|
| [25] |
Lurz P, Besler C, Schmitz T, et al, Short-term outcomes of tricuspid edge-to-edge repair in clinical practice[J]. J Am Coll Cardial,2023,05,008-044.
|
| [26] |
Gray WA, Abramson SV, Lim S, et al. 1-Year outcomes of cardioband tricuspid valve reconstruction system early feasibility study[J]. JACC Cardiovasc Interv, 2022, 15(19):1921-1932.
|
| [27] |
Freixa X, Arzamendi D, Del Trigo M, et al. The TriClip system for edge-to-edge transcatheter tricuspid valve repair. a Spanish multicenter study[J]. Rev EspCardiol (Engl Ed), 2022, 75(10):797-804.
|
| [28] |
Pual S, Rebecca TH. First report of outcomes in the TRILUMINATE Pivota clinical trial of TriClip in patients with tricuspid regurgitation. August 28,2022, ESC Congress.[EB/OL]. [2023-06-01].
URL
|
| [29] |
Wild MG, Löw K, Rosch S, et al. Multicenter experience with the transcatheter leaflet repair system for symptomatic tricuspid regurgitation[J]. JACC Cardiovasc Interv, 2022, 15(13):1352-1363.
|
| [30] |
Zhang Y, Lu F, Li W, et al. A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system[J]. EuroIntervention, 2023, 18(13):e1088-e1089.
|
| [31] |
SCAI Web. First intermediate to long-term study of the harmony transcatheter pulmonary valve system validates safety and efficacy [EB/OL].[2022-06-01].
URL
|
| [32] |
AEPC Web. AEPC 2022 SCientific program overview [EB/OL].[2022-06-01].
URL
|
| [33] |
Price MJ, Slotwiner D, Du C, et al. Clinical outcomes at 1 year following transcatheter left atrial appendage occlusion in the United States[J]. JACC Cardiovasc Interv, 2022, 15(7):741-750.
|
| [34] |
Freeman JV, Higgins AY, Wang Y, et al. Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation[J]. J Am Coll Cardiol, 2022, 79(18):1785-1798.
|
| [35] |
Kapadia S. Late breaking study results reinforce positive real world outcomes with the WATCHMAN FLX ™ LAAC device[EB/OL]. [2022-05-25]. Late Breaking Study Results Reinforce Positive Real World Outcomes with the WATCHMAN FLX TM LAAC Device.
URL
|
| [36] |
Shi S, Tang Y, Zhao Q, et al. Prevalence and risk of atrial fibrillation in China: a national cross-sectional epidemiological study[J]. Lancet Reg Health West Pac, 2022, 23:100439.
|
| [37] |
Haddad RN, Khraiche D, Bonnet D, et al. Preliminary experience with the new Amplatzer™ Trevisio™ delivery system in transcatheter atrial septal defect closures in children[J]. Front Pediatr, 2021, 9:641742.
|
| [38] |
Kavinsky CJ, Szerlip M, Goldsweig AM,et al. SCAI guidelines for the management of patent foramen ovale.[J]. JSCAI, 2022, 4(1):100039-100054.
|
| [39] |
Zhang X, Chen S, Li W, et al. A Novel puncturable atrial septal defect occluder: the results of preclinical experiment and first-in-human study[J]. JACC Basic Transl Sci, 2022, 7(12):1200-1210.
|
| [40] |
Chen L, Hu S, Luo Z, et al. First-in-human experience with a novel fully bioabsorbable occluder for ventricular septal defect[J]. JACC Cardiovasc Interv, 2020 ,13(9):1139-1141.
|
| [41] |
经食道超声心动图临床应用的中国专家共识专家组. 卵圆孔未闭右心声学造影中国专家共识[J]. 中国循环杂志, 2022, 37(5):449-458.
|